Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study. (5th August 2020)

• Record Type: Journal Article
• Authors: Matta, Rano; Hird, Amanda E.; Dvorani, Erind; Saskin, Refik; Nason, Gregory J.; Kulkarni, Girish; Kodama, Ronald T.; Herschorn, Sender; Nam, Robert K.
• Is Part Of: Cancer medicine. Volume 9:Number 19(2020)
• Page Start: 6946
• Page End: 6953
• Publication Date: 2020-08-05
• Subjects: active surveillance -- mortality -- prostate cancer -- prostatic neoplasms -- recurrence; 616.994005
• DOI: 10.1002/cam4.3341
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: The rate of primary and secondary treatment while on active surveillance (AS) for localized prostate cancer at the general population level is unknown. Our objective was to determine the patterns of secondary treatments after primary surgery or radiation for patients who undergo AS. Methods: This was a population‐based retrospective cohort study of men aged 50‐80 years old in Ontario, Canada, between 2008 and 2016. We identified 26 742 patients with prostate cancer, a Gleason grade score ≤7, and an index prostate‐specific antigen ≤10 ng/mL. Patients were categorized as undergoing AS with or without delayed primary treatment (DT; treatment >6 months after diagnosis) versus immediate treatment (IT; treatment ≤6 months). Patients receiving DT and IT were propensity score matched and the rate of secondary treatment (surgery or radiation ± androgen deprivation treatment) was compared using Cox proportional hazards models. Results: We identified 10 214 patients who underwent AS and 11 884 patients who underwent IT. Among patients undergoing AS, 3724 (36.5%) eventually underwent DT and among them, 406 (10.9%) underwent secondary treatment. The median time to DT was 1.2 years (IQR 0.5‐8.1 years). The relative rate of undergoing secondary treatment was similar in the DT vs IT group (HR 0.92; 95% CI: 0.79‐1.08). The risk of death in the DT group was higher compared to patients who did not undergo treatment (HR 1.23, 95% CI: 1.01‐1.49). Conclusions: Among patients with localized prostate cancer on AS, one third undergo DT. The rate of secondary treatment was similar between the DT and IT groups. Patients in the DT group may experience a higher risk of mortality compared to those who remained on AS. Abstract : For men with localized prostate cancer who are candidates for active surveillance, one third receive delayed primary treatment. Active surveillance is a safe approach, as there appears to be no adverse risk of progression with similar rates of secondary treatment compared to patients who underwent immediate treatment.